Adcetris® (brentuximab vedotin) – New indication
November 9, 2017 – Seattle Genetics announced the FDA approval of Adcetris (brentuximab vedotin) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.
Top